|Study to test combination therapy for breast cancer
Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Friday, October 27th, 2017
|Horn to lead lung cancer combination therapy trial
Leora Horn, M.D., M.
Sunday, April 2nd, 2017
|VICC trial putting lung cancer therapy to the test
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]
Thursday, October 20th, 2016
|New prostate cancer therapy investigated at VUMC
Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D.
Thursday, September 22nd, 2016
|VICC treats first patient in Tennessee with novel cellular immunotherapy
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]
Monday, February 29th, 2016
|Study seeks to ease ‘chemobrain’ for cancer patients
Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment. And as the survival rates for breast cancer increase, so do these issues associated with chemotherapy. Paul Newhouse, M.
Monday, August 24th, 2015